<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Study Published In Managed Care Regarding Prognostic and Cancer-Care Planning Value of Biodesix’s VeriStrat® Proteomic Test

A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test

Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer

Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test

Biodesix Presents Cell-free DNA Process Optimization for Liquid Biopsy Test

Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium

Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)

The GeneStrat® Liquid Biopsy Test Earns Approval from NY State-CLEP

The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.

Biodesix® and Positive Bioscience Announce Partnership to Bring Cancer Tests to India

The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India

New Study Shows Advanced Diagnostic Tests, Including the VeriStrat® Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients

A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.

Biodesix Presents Data From Three Studies at AACR Annual Meeting

New Biodesix data on liquid biopsy genomic tests, evaluation of biological processes underlying mass spectrometry proteomic assays of human serum

New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients

VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).

Biodesix Announces Data To Be Presented at AACR Annual Meeting 2017

Biodesix will present data from three studies at AACR 2017 annual meeting, on genomic and proteomic assays.

First 1 2 3 4 5 6 7 8 9 Last